Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from

R J Capocasale1, R J Lamb, E C Vonderheid

  • 1Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.

Insights

Sézary syndrome (SzS) T cells show reduced surface TGF-beta receptor II (TGF beta RII) expression. This defect in receptor transport, not production, may drive SzS development.

Area of Science:

  • Immunology
  • Dermatology
  • Oncology

Background:

  • Sézary syndrome (SzS) is a leukemic form of cutaneous T-cell lymphoma.
  • SzS involves abnormal CD4+ T-cell proliferation and immune dysfunction.
  • Previous studies indicated a reduced response to TGF-beta in SzS T cells.

Purpose of the Study:

  • To investigate defects in transforming growth factor type beta receptor II (TGF beta RII) expression and transport in SzS.
  • To quantify surface and intracellular TGF beta RII levels in SzS CD4+ T cells.

Main Methods:

  • Developed a sensitive flow cytometry method.
  • Detected TGF beta RII on the surface and intracellularly in CD4+ T cells.
  • Compared SzS patient samples with normal CD4+ T cells.

Main Results:

  • CD4+ T cells from 9 out of 12 SzS patients showed significantly reduced surface TGF beta RII expression after mitogen stimulation.
  • Intracellular TGF beta RII levels were comparable between SzS patients and healthy controls.
  • A defect in TGF beta RII trafficking was observed in SzS T cells.

Conclusions:

  • Defective trafficking of TGF beta RII contributes to Sézary syndrome.
  • Reduced surface expression of this inhibitory receptor may impair T-cell regulation in SzS.
  • Targeting TGF beta RII transport could be a therapeutic strategy for SzS.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...